JOP20230283A1 - أنظمة مضادة لـ vegf ممتدة عالية الجرعة لعلاج الاضطرابات وعائية المنشأ بالعين - Google Patents

أنظمة مضادة لـ vegf ممتدة عالية الجرعة لعلاج الاضطرابات وعائية المنشأ بالعين

Info

Publication number
JOP20230283A1
JOP20230283A1 JOJO/P/2023/0283A JOP20230283A JOP20230283A1 JO P20230283 A1 JOP20230283 A1 JO P20230283A1 JO P20230283 A JOP20230283 A JO P20230283A JO P20230283 A1 JOP20230283 A1 JO P20230283A1
Authority
JO
Jordan
Prior art keywords
treatment
regimens
extended
vegf
dose
Prior art date
Application number
JOJO/P/2023/0283A
Other languages
Arabic (ar)
English (en)
Inventor
Thomas Eissing
Friedrich Asmus
Alyson J Berliner
Karen Chu
Silva Leal Sergio Casimiro Da
Kay D Rittenhouse
Robert L Vitti
Original Assignee
Regeneron Pharma
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma, Bayer Healthcare Llc filed Critical Regeneron Pharma
Publication of JOP20230283A1 publication Critical patent/JOP20230283A1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
JOJO/P/2023/0283A 2021-05-17 2023-11-06 أنظمة مضادة لـ vegf ممتدة عالية الجرعة لعلاج الاضطرابات وعائية المنشأ بالعين JOP20230283A1 (ar)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163189541P 2021-05-17 2021-05-17
US202163235398P 2021-08-20 2021-08-20
US202263297420P 2022-01-07 2022-01-07
US202263306315P 2022-02-03 2022-02-03
PCT/US2022/029462 WO2022245739A1 (en) 2021-05-17 2022-05-16 Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders

Publications (1)

Publication Number Publication Date
JOP20230283A1 true JOP20230283A1 (ar) 2023-11-06

Family

ID=81975181

Family Applications (1)

Application Number Title Priority Date Filing Date
JOJO/P/2023/0283A JOP20230283A1 (ar) 2021-05-17 2023-11-06 أنظمة مضادة لـ vegf ممتدة عالية الجرعة لعلاج الاضطرابات وعائية المنشأ بالعين

Country Status (23)

Country Link
US (1) US20230302085A1 (https=)
EP (2) EP4647125A3 (https=)
JP (1) JP2024519629A (https=)
KR (1) KR20240008821A (https=)
AU (2) AU2022275786C1 (https=)
BR (1) BR112023023002A2 (https=)
CA (1) CA3190663A1 (https=)
CL (3) CL2023003396A1 (https=)
DK (1) DK4185318T3 (https=)
ES (1) ES3041647T3 (https=)
FI (1) FI4185318T3 (https=)
HR (1) HRP20251282T8 (https=)
IL (1) IL308505A (https=)
JO (1) JOP20230283A1 (https=)
LT (1) LT4185318T (https=)
MX (1) MX2023013554A (https=)
PE (1) PE20240922A1 (https=)
PL (1) PL4185318T3 (https=)
PT (1) PT4185318T (https=)
RS (1) RS67369B1 (https=)
SI (1) SI4185318T1 (https=)
TW (1) TW202313095A (https=)
WO (1) WO2022245739A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK4364724T3 (da) 2018-05-10 2025-12-22 Regeneron Pharma Formuleringer med høj koncentration af VEGF-receptorfusionsprotein
EP3886946A1 (en) 2019-06-05 2021-10-06 Regeneron Pharmaceuticals, Inc. Devices and methods for precision dose delivery
IL315347A (en) * 2022-03-15 2024-11-01 Regeneron Pharma Prolonged high-dose VEGF antagonist regimens for the treatment of angiogenic ocular disorders
IL315374A (en) * 2022-03-15 2024-11-01 Regeneron Pharma Prolonged high-dose VEGF antagonist regimens for the treatment of angiogenic ocular disorders
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device
CN121712520A (zh) * 2023-06-23 2026-03-20 瑞泽恩制药公司 用于治疗血管生成性眼病的延长的高剂量vegf拮抗剂方案
US20260055171A1 (en) 2024-06-11 2026-02-26 Regeneron Pharmaceuticals, Inc. Vegf antagonists and methods of use thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5288931A (en) * 1991-12-06 1994-02-22 Genentech, Inc. Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation
GB9912350D0 (en) * 1999-05-26 1999-07-28 European Molecular Biology Lab Embl Modified cytokine
US7396664B2 (en) 1999-06-08 2008-07-08 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
FI117667B (fi) * 2001-07-05 2007-01-15 Univ Zuerich Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä
AR046510A1 (es) 2003-07-25 2005-12-14 Regeneron Pharma Composicion de un antagonista de vegf y un agente anti-proliferativo
EP1767546B1 (en) 2004-06-08 2012-03-07 Chengdu Kanghong Biotechnologies Co., Ltd. Angiogenesis-inhibiting chimeric protein and the use
CN100502945C (zh) 2006-03-31 2009-06-24 成都康弘生物科技有限公司 Vegf受体融合蛋白在治疗眼睛疾病中的应用
KR20190049934A (ko) * 2011-01-13 2019-05-09 리제너론 파아마슈티컬스, 인크. 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도
AU2012212047A1 (en) * 2011-02-03 2013-08-22 Xoma Technology Ltd. Methods and materials for enhancing functional protein expression in bacteria
TWI806150B (zh) * 2014-11-07 2023-06-21 瑞士商諾華公司 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物
CA3010862A1 (en) * 2016-01-08 2017-07-13 Clearside Biomedical, Inc. Methods and devices for treating posterior ocular disorderswith aflibercept and other biologics
HUE059827T2 (hu) * 2017-11-30 2023-01-28 Regeneron Pharma VEGF-antagonista alkalmazása angiogén szembetegségek kezelésére
CN117138171A (zh) 2017-12-13 2023-12-01 里珍纳龙药品有限公司 用于精确剂量输送的装置和方法
DK4364724T3 (da) * 2018-05-10 2025-12-22 Regeneron Pharma Formuleringer med høj koncentration af VEGF-receptorfusionsprotein
EP3886946A1 (en) 2019-06-05 2021-10-06 Regeneron Pharmaceuticals, Inc. Devices and methods for precision dose delivery
US20220306732A1 (en) * 2019-09-12 2022-09-29 Lupin Limited Modified dosing of vegf inhibitors for ophthalmic use

Also Published As

Publication number Publication date
KR20240008821A (ko) 2024-01-19
BR112023023002A2 (pt) 2024-01-23
FI4185318T3 (fi) 2025-10-13
AU2022275786A8 (en) 2023-04-20
AU2022275786B2 (en) 2025-06-05
EP4185318B1 (en) 2025-09-03
HRP20251282T8 (hr) 2025-12-19
MX2023013554A (es) 2023-11-29
PT4185318T (pt) 2025-09-29
CL2025001269A1 (es) 2025-08-22
EP4647125A3 (en) 2026-01-28
EP4185318A1 (en) 2023-05-31
PE20240922A1 (es) 2024-04-30
PL4185318T3 (pl) 2026-01-12
WO2022245739A1 (en) 2022-11-24
LT4185318T (lt) 2025-11-10
DK4185318T3 (da) 2025-09-29
SI4185318T1 (sl) 2025-10-30
HRP20251282T1 (hr) 2025-12-05
CA3190663A1 (en) 2022-11-24
IL308505A (en) 2024-01-01
EP4647125A2 (en) 2025-11-12
JP2024519629A (ja) 2024-05-21
RS67369B1 (sr) 2025-11-28
AU2022275786C1 (en) 2025-12-11
CL2023003396A1 (es) 2024-06-07
ES3041647T3 (en) 2025-11-13
AU2025226774A1 (en) 2025-09-25
TW202313095A (zh) 2023-04-01
CL2024002972A1 (es) 2025-01-24
US20230302085A1 (en) 2023-09-28
AU2022275786A1 (en) 2023-04-06

Similar Documents

Publication Publication Date Title
JOP20230283A1 (ar) أنظمة مضادة لـ vegf ممتدة عالية الجرعة لعلاج الاضطرابات وعائية المنشأ بالعين
PH12021500014A1 (en) Fused ring compounds
MX2018003331A (es) Administracion de potenciadores de regulador de la conductancia transmembrana de fibrosis quistica (cftr) deuterados.
MX2022016427A (es) Inhibidores de glicolato oxidasa para el tratamiento de enfermedades.
MA35836B1 (fr) 4 phényl-pyridines substituées pour le traitement de maladies associées à un récepteur nk-1
NZ775964A (en) Animal models, screening methods, and treatment methods for intraocular diseases or disorders
MX2020010968A (es) Formulaciones de bevacizumab tamponadas para usarse en el tratamiento de enfermedades.
JOP20210224A1 (ar) صياغات من المركب 4-(7- هيدروكسي-2- أيزوبروبيل-4- أوكسو-4h- كوينازولين-3- يل)- بنزونيتريل
JOP20240202A1 (ar) أنظمة ممتدة وعالية الجرعة من مضاد vegf لعلاج اضطرابات العين الوعائية
MX2023001450A (es) Composiciones y metodos para la inhibicion de la expresion de plp1.
MX2025013942A (es) Anticuerpos contra mucina 16 y metodos de uso de los mismos
MX2024011132A (es) Regimenes extendidos, con dosis altas de antagonistas de vegf para el tratamiento de trastornos oculares angiogenicos
PH12023552830A1 (en) Compositions and methods for inhibiting ketohexokinase
CO2022006087A2 (es) Métodos para el tratamiento de la trombocitopenia inmunitaria mediante la administración de (r)-2-[3-[4-amino-3-(2-fluoro-4-fenoxi-fenil)pirazolo[3,4-d]pirimidin-1-il]piperidino-1-carbonil]-4-metil-4-[4-(oxetan-3-il)piperazin-1-il]pent-2-enonitrilo
MX2022002418A (es) Composiciones y metodos de tratamiento de enfermedades vasculares.
WO2020142740A8 (en) Treatment of sjogren's disease with nuclease fusion proteins
JOP20230301A1 (ar) تركيبات وطرق لتثبيط التعبير الوراثي عن مكون اختزال أميدوكسيم المتقدري 1 (marc1)
MX2023013207A (es) Anticuerpo agonista anti-pd-1 humano para tratar o prevenir enfermedades inflamatorias, y composicion farmaceutica que contiene el mismo.
MX2025000353A (es) Metodos para tratar el dolor de la superficie ocular
ZA202309651B (en) Compositions and methods for treatment of ocular disease associated with angiogenesis
PH12022552645A1 (en) Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases
EA201992630A1 (ru) Способы лечения заболеваний глаз антагонистами aplnr и ингибиторами vegf
WO2020022438A8 (ja) 網膜線維化を伴う眼疾患の処置剤
WO2020036658A3 (en) Drugs promoting retinal rod photoreceptor survival
JOP20250312A1 (ar) جرعة عالية ممتدة من نظم علاجية لمضاد vegf لعلاج اضطرابات العين وعائية المنشأ